Using lipid nanoparticles to extend telomeres for treating alcoholic hepatitis
TERT mRNA lipid nanoparticles to extend telomeres to treat alcoholic hepatitis
This study is testing a new treatment for alcoholic hepatitis that uses tiny particles to deliver a special type of genetic material to help heal liver cells, with the hope of improving liver health for people struggling with this condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rejuvenation Technologies, INC. NIH-funded |
| Lab location | 1 site (Mountain View, UNITED STATES) |
| Project ID | NIH-10932205 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for alcoholic hepatitis (AH) by utilizing lipid nanoparticles to deliver TERT mRNA, which is believed to help extend telomeres in liver cells. Telomeres are crucial for maintaining the health and regenerative capacity of liver cells, and their shortening is linked to the severity of AH. The study builds on successful animal models that mimic the disease, aiming to translate these findings into potential therapies for humans. By addressing the underlying cellular damage caused by alcohol consumption, this approach seeks to improve liver function and patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcoholic hepatitis, particularly those with severe forms of the disease.
Not a fit: Patients who do not have alcoholic hepatitis or those with liver conditions unrelated to alcohol consumption may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from alcoholic hepatitis, potentially improving liver health and survival rates.
How similar studies have performed: While the approach of using lipid nanoparticles for mRNA delivery is gaining traction, this specific application for alcoholic hepatitis is novel and has not been extensively tested in human subjects.
Where this research is happening
Mountain View, UNITED STATES
- Rejuvenation Technologies, INC. — Mountain View, United States (Active)
Researchers
- Principal investigator: Ramunas, John — Rejuvenation Technologies, INC.
- Study coordinator: Ramunas, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.